Abstract
BackgroundPeptide-based vaccination is a rational option for immunotherapy of prostate cancer. In this first-in-man phase I/II study, we assessed the safety, tolerability and immunological impact of a synthetic long peptide...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have